ISRAEL – Theranica, a prescribed digital therapeutics company in Israel, has signed a strategic licensing pact with Dr. Reddy’s Laboratories Ltd. for the exclusive marketing and distribution of Nerivio® that will be used to treat chronic pain in India.
Nerivio is the first FDA-cleared, prescribed, digitally connected, drug-free wearable device for the acute treatment of episodic and chronic migraine in individuals age 12 and older.
It utilizes remote electrical neuromodulation (REN) to trigger an endogenous descending pain inhibition mechanism known as conditioned pain modulation (CPM), which aborts or alleviates migraine headache and associated migraine symptoms.
Upon completion of the regulatory approval process in India, Theranica and Dr. Reddy’s will work together to ensure Nerivio is accessible to millions of people with migraine in India.
In an official statement, Theranica said: “While the agreement applies only to India, the companies will continue discussions about expanding to additional territories outside the United States and China.”
The digital therapeutics company pointed out that under the exclusive licensing deal, it will manufacture and supply its treatment for chronic pain.
“Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options for acute migraine treatment,” Theranica said.
On the other hand, Dr. Reddy’s will be responsible for the regulatory approval of Nerivio in India, after which it will exclusively market Nerivio in India.
Theranica underscored that the Indian multinational pharmaceutical company will receive licensing fees for exclusive rights to market Nerivio in India for acute migraine treatment.
Through the strategic partnership, Theranica and Dr. Reddy’s will work closely to improve the quality of life of millions of people in India who suffer from this debilitating neurological disorder.
“This agreement aligns exactly with the vision of Theranica’s founders,” said Alon Ironi, Chief Executive Officer (CEO) and Co-founder of Theranica.
He disclosed that the company is working to advance Nerivio as a first-line treatment and contribute to a global paradigm shift in how this debilitating disease is treated.
Moreover, the Israeli corporation recently published topline results of a pivotal trial demonstrating the efficacy and safety of Nerivio® for the preventive treatment of migraine, an indication currently under FDA review.
“The winning combination of Theranica’s neuroscience and digital health R&D with Dr. Reddy’s industry leadership and large commercial footprint will bring Nerivio to millions of people in need of effective migraine therapy.” CEO Ironi underscored.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
